The German method for setting ceiling prices for drugs: In some cases less data are required

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 11, Issue 4, 2011, Pages 403-409

  Gandjour, Afschin ^a   Gafni, Amiram ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

data requirement; drug pricing; Germany; IQWiG; shortcut

Indexed keywords

ARTICLE; CALCULATION; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS; DRUG COST; GERMANY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH SERVICE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE;

COST CONTROL; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION MAKING, ORGANIZATIONAL; DRUG COSTS; GERMANY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; PHARMACEUTICAL PREPARATIONS; QUALITY ASSURANCE, HEALTH CARE;

EID: 80051746228     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.11.45     Document Type: Article

References (12)

1. Institute for Quality and Efficiency in Health Care. General methods for the assessment of the relation of benefits to costs - version 1.0 (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany, 12 October 2009.
2. Caro JJ, Nord E, Siebert U et al. The efficiency frontier approach to economic evaluation of health-care interventions. Health Econ. 19(10), 1117-1127 (2010).
3. Gandjour A. Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules. Appl. Health Econ. Health Policy 9(2), 65-71 (2011).
4. Krauth C, John J, Aidelsburger P et al. Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines [Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System]. Gesundheitswesen 70(6), E1-E16 (2008).
5. Institute for Quality and Efficiency in Health Care. Appraisal of IQWiG's Scientific Advisory Board's recommendations regarding draft version 1.1 (in German). Institute for Quality and Efficiency in Health Care, Cologne, Germany, 16 March 2009.
6. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In:Cost- Effectiveness in Health and Medicine . Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA 176-213 (1996).
7. O'Brien B, Levine M, Willan A et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch. Intern. Med. 159(19), 2298-2304 (1999). (Pubitemid 29501529)
8. Weinstein MC, Zeckhauser R. Critical ratios and efficient allocation. J. Public Econ. 2, 147-157 (1973).
9. Birch S, Gafni A. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J. Health Econ. 11(3), 279-296 (1992).
10. Birch S, Gafni A. Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. J. Health Econ. 12(4), 469-476 (1993). (Pubitemid 24037071)
11. Gandjour A. Aging diseases - do they prevent preventive health care from saving costs? Health Econ. 18(3), 355-362 (2009).
12. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. JAMA 278(21), 1759-1766 (1997 (Pubitemid 27510076)